Akebia Therapeutics to Present at Upcoming Investor Conferences
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, has announced its participation in two upcoming investor conferences in September 2025. The company's executives will present at the Wells Fargo Healthcare Conference in Boston (September 3-5) and the H.C. Wainwright 27th Annual Global Investment Conference in New York (September 8-10).
Chief Financial and Chief Business Officer Erik Ostrowski and Chief Commercial Officer Nik Grund will lead both presentations. The Wells Fargo presentation is scheduled for September 4 at 8:00 AM EDT, while the H.C. Wainwright fireside chat will take place on September 8 at 12:00 PM EDT. Webcasts will be available through Akebia's investor relations website.
Akebia Therapeutics (Nasdaq: AKBA), società biofarmaceutica specializzata nelle malattie renali, ha annunciato la partecipazione a due conferenze per investitori a settembre 2025. I dirigenti presenteranno al Wells Fargo Healthcare Conference a Boston (3-5 settembre) e al H.C. Wainwright 27th Annual Global Investment Conference a New York (8-10 settembre).
Il Chief Financial and Chief Business Officer Erik Ostrowski e il Chief Commercial Officer Nik Grund condurranno entrambe le presentazioni. L’intervento al Wells Fargo è previsto per il 4 settembre alle 8:00 AM EDT, mentre il fireside chat di H.C. Wainwright si terrà l’8 settembre alle 12:00 PM EDT. I webcast saranno disponibili sul sito investor relations di Akebia.
Akebia Therapeutics (Nasdaq: AKBA), una compañía biofarmacéutica centrada en enfermedades renales, ha anunciado su participación en dos conferencias para inversores en septiembre de 2025. Los directivos presentarán en el Wells Fargo Healthcare Conference en Boston (3-5 de septiembre) y en el H.C. Wainwright 27th Annual Global Investment Conference en Nueva York (8-10 de septiembre).
El Chief Financial and Chief Business Officer Erik Ostrowski y el Chief Commercial Officer Nik Grund dirigirán ambas presentaciones. La presentación en Wells Fargo está programada para el 4 de septiembre a las 8:00 AM EDT, y el fireside chat de H.C. Wainwright será el 8 de septiembre a las 12:00 PM EDT. Los webcast estarán disponibles en la web de relaciones con inversores de Akebia.
Akebia Therapeutics (Nasdaq: AKBA), 신장 질환을 중심으로 연구하는 바이오제약사로, 2025년 9월에 열리는 두 차례의 투자자 콘퍼런스에 참가한다고 발표했습니다. 경영진은 보스턴에서 열리는 Wells Fargo Healthcare Conference(9월 3~5일)와 뉴욕에서 열리는 H.C. Wainwright 27th Annual Global Investment Conference(9월 8~10일)에서 발표할 예정입니다.
최고재무·사업책임자(Chief Financial and Chief Business Officer) Erik Ostrowski와 최고상업책임자(Chief Commercial Officer) Nik Grund가 두 발표를 이끕니다. Wells Fargo 발표는 9월 4일 오전 8:00(EDT)에 예정되어 있으며, H.C. Wainwright의 파이어사이드 채팅은 9월 8일 정오(12:00 PM EDT)에 진행됩니다. 웹캐스트는 Akebia 투자자 관계 웹사이트를 통해 제공됩니다.
Akebia Therapeutics (Nasdaq: AKBA), une société biopharmaceutique spécialisée dans les maladies rénales, a annoncé sa participation à deux conférences investisseurs en septembre 2025. Les dirigeants présenteront au Wells Fargo Healthcare Conference à Boston (3-5 septembre) et au H.C. Wainwright 27th Annual Global Investment Conference à New York (8-10 septembre).
Le Chief Financial and Chief Business Officer Erik Ostrowski et le Chief Commercial Officer Nik Grund animeront les deux présentations. L’intervention au Wells Fargo est prévue le 4 septembre à 8h00 EDT, tandis que le fireside chat de H.C. Wainwright aura lieu le 8 septembre à 12h00 EDT. Des webcasts seront disponibles via le site relations investisseurs d’Akebia.
Akebia Therapeutics (Nasdaq: AKBA), ein Biopharmaunternehmen mit Fokus auf Nierenerkrankungen, hat seine Teilnahme an zwei Investorenkonferenzen im September 2025 angekündigt. Die Unternehmensleitung wird beim Wells Fargo Healthcare Conference in Boston (3.–5. September) und beim H.C. Wainwright 27th Annual Global Investment Conference in New York (8.–10. September) präsentieren.
Chief Financial and Chief Business Officer Erik Ostrowski und Chief Commercial Officer Nik Grund werden beide Präsentationen leiten. Die Präsentation bei Wells Fargo ist für den 4. September um 8:00 Uhr EDT geplant, das Fireside-Chat bei H.C. Wainwright findet am 8. September um 12:00 Uhr EDT statt. Webcasts sind über die Investor-Relations-Website von Akebia verfügbar.
- None.
- None.
CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its executives will participate in two investor conferences in September: Wells Fargo Healthcare Conference on September 3-5, 2025 in Boston and H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025 in New York.
Wells Fargo Healthcare Conference
Erik Ostrowski, Chief Financial and Chief Business Officer, and Nik Grund, Chief Commercial Officer, will present on Thursday, September 4 at 8:00 AM EDT.
H.C. Wainwright Global Investment Conference
Mr. Ostrowski and Mr. Grund will participate in a fireside chat on Monday, September 8 at 12:00 PM EDT.
A webcast of each presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com following the conferences.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
FAQ
When is Akebia Therapeutics (AKBA) presenting at the Wells Fargo Healthcare Conference 2025?
Who will be presenting at Akebia's (AKBA) September 2025 investor conferences?
When is Akebia's (AKBA) presentation at the H.C. Wainwright Conference 2025?
How can investors access Akebia Therapeutics' (AKBA) conference presentations?
